Compare Hemas Holdings Plc with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
LKR 98,854 Million (Large Cap)
11.00
NA
0.00%
-0.00
16.59%
1.86
Revenue and Profits:
Net Sales:
31,540 Million
(Quarterly Results - Mar 2026)
Net Profit:
3,133 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.28%
0%
-8.28%
6 Months
-12.68%
0%
-12.68%
1 Year
24.5%
0%
24.5%
2 Years
74.35%
0%
74.35%
3 Years
-50.79%
0%
-50.79%
4 Years
249.1%
0%
249.1%
5 Years
-61.25%
0%
-61.25%
Hemas Holdings Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.00%
EBIT Growth (5y)
20.53%
EBIT to Interest (avg)
6.95
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.13
Sales to Capital Employed (avg)
2.05
Tax Ratio
35.76%
Dividend Payout Ratio
33.36%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.07%
ROE (avg)
14.05%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
1.81
EV to EBIT
7.74
EV to EBITDA
6.53
EV to Capital Employed
1.81
EV to Sales
0.76
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
23.35%
ROE (Latest)
16.59%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
31,540.30
35,009.00
-9.91%
Operating Profit (PBDIT) excl Other Income
4,218.80
4,615.30
-8.59%
Interest
353.30
235.20
50.21%
Exceptional Items
0.00
0.00
Consolidate Net Profit
3,132.60
2,743.90
14.17%
Operating Profit Margin (Excl OI)
115.10%
115.00%
0.01%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -9.91% vs 8.43% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 14.17% vs 27.01% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
127,362.00
117,970.20
7.96%
Operating Profit (PBDIT) excl Other Income
15,245.10
14,160.30
7.66%
Interest
1,020.40
1,500.40
-31.99%
Exceptional Items
109.00
336.20
-67.58%
Consolidate Net Profit
9,292.20
8,338.70
11.43%
Operating Profit Margin (Excl OI)
101.50%
103.10%
-0.16%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 7.96% vs -3.00% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 11.43% vs 31.22% in Mar 2025
About Hemas Holdings Plc 
Hemas Holdings Plc
Pharmaceuticals & Biotechnology
Hemas Holdings PLC (Hemas) is a Sri Lanka-based pharmaceuticals company engaged in healthcare, leisure and transportation services. The Company operates in various segments, such as FMCG, Healthcare, Leisure, Transportation, Power and others. The FMCG business sector manufactures and markets personal care and home care branded products. Its Healthcare sector is a distributor of pharmaceuticals, surgical and diagnostic products in Sri Lanka. Its Leisure sector consists of the Serendib Leisure Group of Hotels. The Transportation sector consists of the aviation business both in the passenger and cargo segments, its maritime business providing feeder operations and agency services for international shipping partners, its outbound travel agency services via Hemas Travels and its logistics business unit consists of integrated logistic services.
Company Coordinates 
Company Details
No 75, Braybrooke Place, Colombo 02 , COLOMBO None : 01
Registrar Details






